Sonelokimab (SLK)

Search documents
MoonLake Immunotherapeutics (MLTX) 2025 Earnings Call Presentation
2025-04-29 19:17
Clinical Trial Updates - VELA Phase 3 program in Hidradenitis Suppurativa (HS) has completed recruitment as planned, twice as fast as the industry benchmark[17] - VELA baseline characteristics replicate the MIRA baseline, allowing comparison with key competitors[17] - Interim efficacy and safety data from the Phase 2 PPP LEDA program show a unique profile for Sonelokimab (SLK) in Palmoplantar Pustulosis (PPP)[17] - The LEDA trial is fully enrolled since mid-April 2025, measuring objective endpoints such as AI-images, tissue & peripheral blood biomarkers[95] Market Analysis - The Hidradenitis Suppurativa (HS) market is projected to grow to $10-15 billion+ by 2035[45] - Real-world data indicates approximately 2.5 million US patients are already diagnosed and treated for HS[64] - Only ~3% of HS patients are treated with biologics, suggesting a significant opportunity for market penetration[64] - The Palmoplantar Pustulosis (PPP) market is estimated to be worth $3-4 billion in 2038[68] Financial Highlights - MoonLake closed a non-dilutive debt facility providing access to up to $500 million to support growth[99] - The first tranche of $75 million was received in March 2025, with an 8.95% cash interest rate[100]